(Tiper Stock Exchange) – Garofalo Health Care (GHC), a company listed on Euronext STAR Milan and one of the main operators in the accredited private healthcare sector in Italy, closed the 2022 with revenues consolidated amounting to 322.6 million euros, an increase of 13.7% compared to 2021. These results include the contribution over 12 months of Clinica S. Francesco and Domus Nova, structures acquired, respectively, in April and July 2021 and the contribution of 1 month of GVDR, acquired in December 2022. A equal perimeteror excluding the GVDR contribution for 1 month for 2022, revenues are up by 3.8%.
L’Operating EBITDA Adjusted consolidated financial year 2022 amounted to 58.6 million euros, up by 10.3%, despite higher energy costs. The Net income of the Group amounted to 21.4 million euros, with an increase of 2.6 million euros.
“I am particularly proud of the results economic and financial results produced by the Group in 2022 which, despite the exceptional complexity of the macroeconomic scenario of the period, showed, on a like-for-like basis, significant growth, both in terms of revenues and margins and profits – commented theCEO Maria Laura Garofalo – A growth trend which, moreover, is confirmed and strengthened also in the first 2 months of 2023″.
As at 31 December 2022 the Net Financial Position (NFP) of GHC is equal to 145 million euros, given by liquidity for 31.6 million euros and financial debt for 176.6 million euros.
Approved the new buyback plan up to 3% of the share capital, which will be submitted to the shareholders’ meeting called for next 28 April.